Skip to Content

What is the difference between Udenyca and Neulasta?

What is a biosimilar?

Medically reviewed by Last updated on Sep 19, 2019.

Official Answer


Udenyca (pegfilgrastim-cbqv) is a biosimilar to Neulasta (pegfilgrastim).

A biosimilar is a biological product that is very similar to a reference biologic (such as Neulasta) and for which there are no clinically meaningful differences in terms of safety, purity, and potency.

Neulasta and Udenyca are classified as colony-stimulating factors. Colony stimulating factors are used in patients who are undergoing cancer treatments that cause low white blood cell counts (neutropenia) and puts the patient at risk of infection. These medications boost production of white blood cells in response to infection and help to reduce the time when a patient is neutropenic.

For more information, see What Are Biosimilars? Top Facts You May Not Know

Related Medical Questions

Drug Information

Related Support Groups